SCYNEXIS Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
June 03, 2022 16:05 ET
|
Scynexis
JERSEY CITY, N.J., June 03, 2022 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ: SCYX), a biotechnology company pioneering innovative medicines to overcome and prevent difficult-to-treat and...
SCYNEXIS to Present at Upcoming H.C. Wainwright Global Investment Conference
May 20, 2022 08:30 ET
|
Scynexis
JERSEY CITY, N.J., May 20, 2022 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ: SCYX), a biotechnology company pioneering innovative medicines to overcome and prevent difficult-to-treat and...
SCYNEXIS Reports First Quarter 2022 Financial Results and Provides Corporate Update
May 12, 2022 07:00 ET
|
Scynexis
BREXAFEMME® (ibrexafungerp tablets), launched in September 2021 for the treatment of vulvovaginal candidiasis (VVC), achieved almost 4,000 prescriptions with net revenues of $0.7 million in Q1 2022....
SCYNEXIS Presents New Interim Positive Data of Ibrexafungerp for Refractory Vulvovaginal Candidiasis from Ongoing Phase 3 FURI Study at the American College of Obstetricians and Gynecologists (ACOG) Annual Clinical & Scientific Meeting
May 10, 2022 08:30 ET
|
Scynexis
Data show that of the FURI study patients with refractory or relapsed vulvovaginal candidiasis (VVC) treated with ibrexafungerp, 71.4% had successful clinical outcomes. Ibrexafungerp demonstrated...
SCYNEXIS to Report First Quarter 2022 Financial Results and Provide a Corporate Update on May 12
May 05, 2022 08:30 ET
|
Scynexis
JERSEY CITY, N.J., May 05, 2022 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ: SCYX), a biotechnology company pioneering innovative medicines to overcome and prevent difficult-to-treat and...
SCYNEXIS to Present New Data of Ibrexafungerp for Refractory Vulvovaginal Candidiasis from Ongoing Phase 3 FURI Study at the American College of Obstetricians and Gynecologists (ACOG) Annual Clinical & Scientific Meeting
May 04, 2022 08:30 ET
|
Scynexis
JERSEY CITY, N.J., May 04, 2022 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ: SCYX), a biotechnology company pioneering innovative medicines to overcome and prevent difficult-to-treat and...
SCYNEXIS Presents Data Analyses Showing Ibrexafungerp’s Potential to Fight Invasive Candidiasis and Candidemia, Including Infections Caused by Candida Auris, During the 32nd Annual European Congress of Clinical Microbiology & Infectious Diseases
April 27, 2022 08:30 ET
|
Scynexis
New interim analysis of the Phase 3 CARES study showed complete or partial response in 78% of the 18 patients treated with ibrexafungerp for infections caused by Candida auris, a potentially deadly...
SCYNEXIS Announces Closing of $45 Million Public Offering of Common Stock, Pre-Funded Warrants and Warrants
April 26, 2022 17:18 ET
|
Scynexis
JERSEY CITY, N.J., April 26, 2022 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (Nasdaq: SCYX) today announced the closing of its previously announced underwritten public offering of common stock, pre-funded...
SCYNEXIS Announces Pricing of $45 Million Public Offering of Common Stock, Pre-Funded Warrants and Warrants
April 22, 2022 08:15 ET
|
Scynexis
JERSEY CITY, N.J., April 22, 2022 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (Nasdaq: SCYX) today announced the pricing of its underwritten public offering of common stock, pre-funded warrants and warrants....
SCYNEXIS Announces Positive Interim Data from Phase 3 FURI and CARES Studies Highlighting Oral Ibrexafungerp's Potency Against Severe Fungal Infections
April 22, 2022 08:00 ET
|
Scynexis
Data reinforce findings from previous analyses demonstrating oral ibrexafungerp’s potential to combat difficult-to-treat and refractory fungal infections in the hospital setting.Ongoing FURI and CARES...